Alle Storys
Folgen
Keine Story von Medigene AG mehr verpassen.

Medigene AG

ots Ad hoc-Service: MediGene AG <DE0005020903> ACQUISITION OF NEUROVIR THERAPEUTICS, INC. BY MEDIGENE AG: INFORMATION MEMORANDUM DISTRIBUTED

Munich (ots Ad hoc-Service) -

Ad hoc-announcement edited and sent by DGAP. The sender is solely
responsible for the contents of this announcement.
The closing of the acquisition of the biopharmaceutical company
NeuroVir Therapeutics, Inc. (San Diego, CA) by MediGene AG (Munich,
Germany, NMarkt: MDG) is almost completed. The last major step is the
consent of NeuroVir shareholders' to the merger agreement which was
signed by both companies in November 2000. The respective
shareholders' meeting is scheduled for January 2001. Today, MediGene
announced the distribution of an information memorandum to NeuroVir
shareholders in compliance with U.S. and Canadian securities laws.
The information memorandum contains, among other things, consolidated
pro forma financial statements for the companies. To better conform
to U.S. and Canadian accounting practices, the presentation of the
cash flow statement in the information memorandum was modified,
MediGene wants to provide all its existing and potential shareholders
with the same updated information. Therefore, the information
memorandum has been placed for downloading on MediGene's website
(http://www.medigene.de). MediGene also will provide a copy of the
information memorandum upon request (Contact: Mr. Michael
Nettersheim, Investor Relations Manager).
For further information please contact:
MediGene AG email:  investor@medigene.de fax: ++49-89-89 56 32-20
Christine Bohner, Public Relations phone: ++49-89-89 56 32-16
Michael Nettersheim, Investor Relations phone: ++49-89-89 56 32-46
End
Internet: http://recherche.newsaktuell.de

Original-Content von: Medigene AG, übermittelt durch news aktuell

Weitere Storys: Medigene AG
Weitere Storys: Medigene AG
  • 21.08.2000 – 07:45

    ots Ad hoc-Service: MediGene AG <DE0005020903>

    Munich-Martinsried (ots Ad hoc-Service) - Developer of therapeutics against heart and tumor diseases publishes healthy half year report Stock market newcomer MediGene presents first half year report - The biopharmaceutical company MediGene AG (NMarkt: MDG) succeeded in continuing its positive growth trend of the year 1999 and reports a very successful flow of business according to US-GAAP figures: in ...